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MAYO, MYRIAD, AND THE FUTURE OF INNOVATION IN
MOLECULAR DIAGNOSTICS AND PERSONALIZED MEDICINE
Christopher M. Holman*
Contrary to popular perception, the Supreme Court's recent
decision in Association for Molecular Pathology v. Myriad
Genetics, Inc., finding certain patent claims reciting isolated
genomic DNA molecules patent ineligible is likely to have a
relatively minor impact on the patenting of diagnostics and
personalized medicine. Method claims generally play a much more
important role than isolated DNA claims in the patenting of
innovations in this important technological sector, and the Court's
earlier decision in Mayo v. Prometheus Labs that held claims
directed towards non-genetic methods of personalized medicine to
be patent ineligible will likely prove significantly more problematic
in this regard. This article analyzes Myriad and Mayo and
discusses their implications, concluding with a critique of Ariosa
Diagnostics v. Sequenom, a district court decision applying Mayo
to genetic diagnostic method claims in a manner that, iffollowed
by other courts, could substantially threaten the availability of
adequate patent protection for molecular diagnostics and
personalized medicine.
* Christopher M. Holman, Ph.D., J.D. is a Professor of Law at the University
of Missouri-Kansas City.
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I. INTRODUCTION
On June 13, 2013, the U.S. Supreme Court issued a unanimous
decision in Association for Molecular Pathology v. Myriad
Genetics, Inc.' invalidating patent claims directed toward isolated
DNA molecules derived from the human genome. Some celebrated
the decision, calling it a "victory for all those eagerly awaiting
more individualized, gene-based approaches to medical care," 2 but
others, particularly innovators in biotechnology, have expressed
concern that the heightened standard for patent eligibility
established by Myriad will substantially weaken the incentive for
1133 S. Ct. 2107 (2013) [hereinafter Myriad].
2 See, e.g., Francis S. Collins, Statement by NIH Director Francis Collins on
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investment in this important technological sector. 3 Particularly
troubling is the disruption of investment-backed expectations
caused by this reversal of long-standing United States Patent and
Trademark Office ("PTO") policy.4
The avowed purpose of the Myriad plaintiffs was to invalidate
patent claims that they alleged broadly covered clinical and
research applications of breast cancer gene ("BRCA") genetic
testing. Some of the challenged patent claims were in fact
explicitly directed towards genetic testing, particularly claims
reciting methods of testing for genetic variations in BRCA genes. 6
Many of the challenged claims, however, were not at all likely to
be infringed by genetic testing or research, particularly product
claims directed towards isolated DNA molecules.' Nonetheless, the
plaintiffs and the courts seem to have assumed that the isolated
DNA product claims were highly relevant to genetic testing, and
these were the only claims that were actually addressed by the
Supreme Court.'
Curiously, given that the plaintiffs' arguments for standing
were based on a purported desire for greater access to BRCA
genetic diagnostic testing,9 one of the challenged claims on its face
had absolutely nothing to do with genetic testing. This was Claim
20 of U.S. Patent Number 5,747,282, which is directed towards
methods for screening for potential cancer therapeutics. 10 The
3See, e.g., Roy Zwahlen, Myriad Supreme Court Decision: BIO's Statement,
BIOTECHNOW (June 13, 2013), http://www.biotech-now.org/public-policy/pate
ntly-biotech/2013/06/myriad-supreme-court-decision-bios-statement#.
4 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d
1303, 1343-45 (Fed. Cir. 2012).
' Sandra Park, Today's the Day: Challenging Human Gene Patents Before the
Supreme Court, Am. CIVIL LIBERTIES UNION (Apr. 15, 2013, 10:16 AM), https://
www.aclu.org/blog/womens-rights-free-speech-technology-and-liberty/todays-
day-challenging-human-gene-patents.
6 See, e.g., U.S. Patent No. 5,709,999 col. 161 (filed June 7, 1995).
7 See U.S. Patent No. 5,747,282 col. 153 (filed June 7, 1995).
8 The diagnostic testing method claims were invalidated by the Federal Circuit
and not addressed by the Supreme Court. Ass'n for Molecular Pathology v. U.S.
Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011).
9 Id. at 1344.
10 Id. at 1343-45.
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Myriad plaintiffs' decision to challenge a patent claim solely
directed to drug discovery, with no nexus to genetic testing or
research," raises serious questions regarding their true motives.
However, this aspect of the case will not be the subject of this
Article.
Instead, this Article will focus on the impact of the Court's two
most recent patent eligibility decisions on the availability of
effective patent protection for diagnostic tests and personalized
medicine. Myriad captured public attention, due in large part to the
public relations efforts of the lawyers representing the plaintiffs,
including their provocative, albeit misleading question for review
in the petition for certiorari, i.e., "are human genes patentable?"12
However, Mayo Collaborative Services v. Prometheus
Laboratories,13 a patent eligibility case decided by the Supreme
Court a year before Myriad, is likely to be more significant, and
indeed more problematic, for those seeking patent protection for
innovative diagnostic tests and personalized medicine than the
Myriad decision.
This Article begins in Part II with a brief introduction to some
basic technical aspects of molecular diagnostic testing and
personalized medicine. Part III explains why, contrary to popular
perception, Myriad is likely to have a relatively minimal impact on
the patenting of innovations in diagnostics and personalized
medicine. Part IV proposes a plausible policy basis for the
disparate treatment of isolated genomic DNA and cDNA claims in
Myriad. Part V explains the importance of method claims in the
patenting of diagnostic-based inventions, and Part VI also
discusses the potential impact of Mayo on patenting in this
important area of technology. Finally, Part VII examines Ariosa
Diagnostics, a recent decision from the Northern District of
California that applies Mayo to genetic diagnostic method claims
" Ryan Abbot, Thoughts on Myriad, HARVARD L. PETRIE-FLOM CTR. (June
14, 2013), https://blogs.law.harvard.edu/billofhealth/2013/06/14/thoughts-on-my
riad/#more-6517.
12 Appellate Petition, Ass'n for Molecular Pathology v. Myriad Genetics, Inc.,
133 S. Ct. 2107 (2013) (No. 12-398), 2012 WL 4502947.
13 132 S. Ct. 1289 (2012) [hereinafter Mayo].
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in a manner that, if followed by other courts, could substantially
threaten the availability of adequate patent protection for molecular
diagnostics and personalized medicine.
II. MOLECULAR DIAGNOSTIC TESTING AND
PERSONALIZED MEDICINE
As a prelude to this Article's discussion of the impact of Mayo
and Myriad, this Part provides a brief introduction to some basic
technical aspects of molecular diagnostic testing and personalized
medicine. Readers familiar with the technology might choose to
skip this Part.
A. Molecular Diagnostics Testing
The terms "molecular diagnostics" and "molecular diagnostic
testing" refer to methodologies used to assess some medically
significant characteristic of a patient based on the detection, and
often quantification, of one or more molecular biomarkers. 14
Molecular diagnostic tests are often DNA-based, and are premised
on the correlation between a genetic biomarker and some
phenotype of clinical significance. 15 The biomarker in a typical
DNA-based genetic test is a genetic variation, sometimes referred
to as a mutation, or some combination of genetic variations. 16
These genetic biomarkers are typically detected by determining the
sequence of nucleotides at a relevant location in a patient's genome
in order to test for the presence of the variation.17
The BRCA tests at issue in Myriad fall into this category of
DNA-based genetic tests. The BRCA genes code for proteins that
play a significant role in warding off cancer." Some individuals
have BRCA genes with variations (sometimes referred to as
14 Linnea M. Baudhuin, Leslie J. Donato & Timothy S. Uphoff, How Novel
Molecular Diagnostic Technologies and Biomarkers are Revolutionizing
Genetic Testing and Patient Care, 12.1 EXPERT REV. OF MOLECULAR
DIAGNOSTICS 25 (2012); MOuSuMI DEBNATH ET AL., MOLECULAR
DIAGNOSTICS: PROMISES AND POSSIBILITIES v vii (18th ed. 2010).
" DEBNATH ET AL., supra note 14, at 106.
16 Myriad, 133 S. Ct. at 2112; DEBNATH ET AL., supra note 14, at 106.
17 Myriad, 133 S. Ct. at 2112-13.
18 Id.
N.C. J.L. & TECH.
mutations) that attenuate the ability of the encoded protein to
prevent cancer, thus rendering an individual possessing these
variations in her BRCA genes more susceptible to certain forms of
cancer. 19 BRCA testing is normally conducted by a clinical
laboratory, and involves amplifying portions of the patient's DNA
by methodologies such as polymerase chain reaction ("PCR").20
The synthetic copies of the genomic DNA molecules resulting
from amplification are then analyzed for the presence of genetic
variations associated with an altered susceptibility to cancer. 2 1
There are also other types of DNA-based diagnostic tests that
look for biomarkers other than genetic sequence variations. For
example, many diagnostic tests are based on the level at which a
gene (or genes) is (are) expressed in an individual. 22 A gene, as it
exists in the human genome, is the functional analog of a blueprint,
and "expression" refers to processes by which the gene is
essentially "turned on," such that the blueprint is actually used as a
template for the production of a biologically significant product,
typically a protein encoded by that gene. 23 Expression of a gene
involves the production of messenger RNA ("mRNA") copies of
the gene, which then serve as the intermediary between the gene
and protein expression. 24 The extent to which a gene is active and
"turned on" in a patient can be measured by how many mRNA
19 Id.
20 Robert Cook-Deegan et al., Impact of Gene Patents and Licensing Practices
on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing
Breast and Ovarian Cancers with Colon Cancers, 12 GENETICS IN MED. 15, S16
(2010).
21 Id.
22 Information That Can Help Define Treatment Options and Make Treatment
Decisions for Breast (early-stage and DCIS), Colon and Prostate Cancer
Patients, GENOMIC HEALTH, http://www.genomichealth.com/en-US/Oncotype
DX.aspx (last visited Apr. 4, 2014) (describing a commercially available test);
Laura Hoopers, Genetic Diagnosis: DNA Microarrays and Cancer, NATURE
(2008), http://www.nature.com/scitable/topicpage/genetic-diagnosis-dna-microarrays-
and-cancer-1017.
23 Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11
MINN. J.L. SCI. & TECH. 157, 170-72 (2010).
24 Id. at 172.
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copies of the gene are present in the cells.25 Many diagnostic tests
have been developed which correlate some medically significant
phenotype with the level of expression of certain genes, as
determined by measuring mRNA levels of the genes, typically
using a cDNA microarray2 6 or "gene chip."27 In many cases it is
easier to work with a synthetic DNA copy of mRNA, known as
complementary DNA ("cDNA"), which is a form of DNA that
garnered much of the Supreme Court's attention in Myriad.2 8
Molecular diagnostics are not limited to DNA-based tests,
because the biomarker could be any other physiologically relevant
biomolecule, such as a protein, lipid, carbohydrate, or small-
molecule hormone.2 9 In the first of the five recent patent eligibility
grants of certiorari, LabCorp v. Metabolite,3 0 the biomarker was a
hormone, and the test was based on the discovery of a correlation
between levels of that hormone and a vitamin deficiency in the
patient.3 1 In Mayo, the biomarker was a drug metabolite, i.e., the
physiological breakdown product of a drug in a patient's blood,
and the claimed diagnostic test was based on the discovery of a
correlation between the level of biomarker in a patient's blood and
optimal dosage of the drug.32 Although Mayo did not involve a
genetic diagnostic test, its holding is clearly relevant to molecular
diagnostic tests in general, as borne out by the role it played in the
25 Martin Bengtsson et al., Gene Expression Profiling in Single Cells from the
Pancreatic Islets of Langerhans Reveals Lognormal Distribution of mRNA
Levels, 15 GENOME RES. 1388, 1388 (2005).
26 Kai Wang et al., Monitoring Gene Expression Profile Changes in Ovarian
Carcinomas Using cDNA Microarray, 229 GENE 101, 101-08 (1999).
27 Chris Zanazzi et al., Gene Expression Profiling and Gene Copy-Number
Changes in Malignant Mesothelioma Cell Lines, 46 GENES, CHROMOSOME &
CANCER 895, 900 (2007).
28 Axel Wellmann et al., Detection of Differentially Expressed Genes in
Lymphomas Using cDNA arrays: Identification of Clusterin as a New
Diagnostic Marker for Anaplastic Large-cell Lymphomas, 96 BLOOD 398, 403
(2000).
29 Anupam Talapatra et al., Protein Microarrays: Challenges and Promises,
3(4) PHARMACOGENOMICS 527, 527-32 (2002).
30 Lab Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124 (2006).
31 Id. at 125.
32 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 132 S. Ct. 1289, 1295
(2012).
N.C. J.L. & TECH.
invalidation of genetic diagnostic testing claims at issue in Ariosa
Diagnostics v. Sequenom.33
Diagnostic tests are important for a number of reasons,
particularly as tools for enabling patients and their healthcare
providers to make more informed medical decisions. For an
extreme example of this, we need look no further than the well-
publicized decision of Angelina Jolie to undergo double
mastectomy based on the results of a BRCA test showing genetic
variations associated with a high likelihood of developing breast
cancer. 34 The tests at issue in LabCorp, used to detect vitamin
deficiencies, might provide a patient with information that would
lead the patient to begin taking vitamin supplements. A genetic test
that shows an individual has a heightened likelihood of developing
heart disease might lead that individual to stop smoking cigarettes
and start exercising more.
B. Personalized Medicine
Historically, molecular diagnostic testing has played a
relatively minor role in healthcare, but the landscape around
diagnostics seems to be changing. 3 One particularly significant
development in this regard is personalized medicine. Personalized
medicine represents a pairing of molecular diagnostics and medical
intervention, particularly by means of pharmaceutical therapy. 36
Using diagnostic testing, it is becoming increasingly possible to
identify a specific drug and treatment regimen for a patient based
on that individual patient's own physiological requirements. One
example is the use of genetic testing to identify that subset of
breast cancer patients who will be amenable to treatment by the
biotechnology drug Herceptin. It turns out that Herceptin is highly
33 No. C 11-06391 SI, 2013 WL 5863022, at *6-11 (N.D. Cal. Oct. 30, 2013);
see infra Part VII.
34 Angelina Jolie, My Medical Choice, N.Y. TIMES (May 14, 2013), available
at http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html? r=0.
35 George Poste, Molecular Diagnostics: A Powerful New Component of the
Healthcare Value Chain, 1 EXPERT REV. MOLECULAR DIAGNOSTICS 1, 1 (2001).
36 Personalized Medicine Today & Tomorrow, INNOVATION.ORG, http://www.
ageofpersonalizedmedicine.org/personalized-medicine/ (last visited Mar. 31,
2014).
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effective for some breast cancer patients, but largely ineffective for
others, and diagnostic testing plays a critical clinical role in
distinguishing between the two.37 The claims at issue in Mayo
provide another example of personalized medicine, by providing a
molecular diagnostic test that informs healthcare providers as to
the appropriate dosage of drug for an individual patient.
III. MYRIAD WILL LIKELY HAVE A RELATIVELY MINOR IMPACT
ON THE PATENTING OF DIAGNOSTICS
Ironically, while the plaintiffs purported motivation in suing
Myriad was to provide freedom to operate for laboratories engaged
in BRCA genetic testing,38 it seems doubtful that the decision will
have a major impact on the patenting of innovative genetic tests.
Although the PTO recently issued guidance for patent examiners in
applying Myriad and Mayo,3 9 it is important to bear in mind that it
is ultimately up to the courts, not the PTO, to interpret patent law.
For example, the PTO issued guidance finding isolated DNA
molecules to be patent eligible, 40 and the Court in Myriad showed
little if any deference in overruling the PTO's interpretation of the
law.4 1 As of yet, the courts have not had occasion to apply Myriad
to DNA product claims, and patent attorneys and biotechnology
firms are unsure how broadly the decision will be interpreted. In
any event, the impact of Myriad will largely be limited to isolated
DNA claims that will, in the author's view, not be particularly
important for the patenting of new diagnostics. Part of the problem
with Myriad is that the case was brought as a declaratory judgment
action, and the patent owner had never alleged that any of the
claims before the Supreme Court were infringed by any form of
3 What is Personalized Medicine?, INNOVATION.ORG, http://www.ageofperson
alizedmedicine.org/what ispersonalized medicine/ (last visited Mar. 31, 2014).
38 Ass'n of Molecular Biology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2114
(2013).
39 U.S. PATENT & TRADEMARK OFFICE, 2014 PROCEDURE FOR SUBJECT
MATTER ELIGIBILITY ANALYSIS OF CLAIMS RECITING OR INVOLVING LAWS OF
NATURE/NATURAL PRINCIPLES, NATURAL PHENOMENA, AND/OR NATURAL
PRODUCTS, available at http://www.uspto.gov/patents/law/examc/memoranda.jsp.
40 See U.S. Patent & Trademark Office, Utility Examination Guidelines, 66
Fed. Reg. 1092 (2001).
41 Myriad, 133 S. Ct. at 2115, 2118-19.
N.C. J.L. & TECH.
genetic testing.42 There was no specific product or service alleged
to infringe the claims, and perhaps for that reason the district court
felt it was unnecessary to hold a Markman hearing or to engage in
a thorough construction of the claims. 4 3
A. Native-Source DNA vs. Synthetic DNA
In particular, the claims at issue in Myriad recite "isolated"
DNA, and prior to Myriad "isolation" had always been understood
to play a critical role in distinguishing between patent ineligible
naturally occurring DNA and patent eligible isolated DNA. 4 The
Supreme Court ultimately declared "isolated genomic DNA"
patent ineligible, but without ever adequately addressing the
meaning of the critical term "isolated." Most significantly, the
Supreme Court never clarified whether its holding that isolated
genomic DNA is patent ineligible was limited to native source
DNA (i.e., DNA that originated in, and has been extracted from, a
natural source, such as a naturally occurring human cell), or
whether the Court also considered synthetic DNA having the same
sequence of nucleotides as a segment of naturally occurring
genomic DNA to be patent ineligible. The distinction is of crucial
importance, because all conventional forms of genetic testing
involve the use of synthetic copies of genomic DNA. 45 For that
matter, essentially any practical application of genomic DNA
sequences involves the use of synthetic copies of genomic DNA,
including the vast majority of molecular biology research. 46 If the
holding in Myriad is limited to native source DNA the decision
should have virtually no impact on genetic testing. Ironically, any
impact Myriad might have will likely be limited to non-DNA
biomolecules, which are much more likely to be purified from a
4 21d. at 2114.
43 See Markman Hearing, WIKIPEDIA, http://en.wikipedia.org/wiki/Markman
hearing (last visited Mar. 31, 2014).
4 U.S. PATENT & TRADEMARK OFFICE, supra note 39.
45 Brief for Law Professor Christopher M. Holman as Amicus Curiae
Supporting Neither Party, Myriad, 133 S. Ct. 2107 (2013) (No. 2010-1406),
2012 WL 2884112.
46 Id.
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native source in usable quantities than DNA, because unlike DNA
these molecules cannot be amplified. 47
In large part, the reason DNA biomarkers make such useful
and important targets for molecular diagnostic testing is that DNA
is uniquely amenable to amplification, which can be used to create
an unlimited number of synthetic copies retaining the nucleotide
sequence of a native source DNA molecule. 48 To illustrate,
consider the fact that changes to the BRCA protein are the direct
cause of increased risk of cancer, but that we detect these
variations indirectly by detecting variations in the DNA that codes
for the protein, not directly in a patient's BRCA protein. The
reason is that protein does not serve as a template for the
production of synthetic copies, and as a result it would be quite
difficult, if not impossible, to isolate sufficient protein to analyze
for variations. Clearly Myriad's patents would not cover direct
testing of BRCA proteins, so plaintiffs' allegations that Myriad's
patents provide complete coverage of BRCA testing implies that
they considered direct testing of the protein an inadequate
substitute for DNA-based testing.
Even when a fragment of genomic DNA (such as a BRCA
gene, in whole or in part) is "isolated" for the first time, what is
normally "isolated" is not DNA that originated in a naturally
occurring human genome, but instead is synthetic DNA produced
in a laboratory with the same DNA sequence as native-origin
DNA. To better convey this point, it might be useful to provide a
brief overview of the methodology typically involved in
"isolating" a fragment of genomic DNA for the first time. The
process begins with the extraction of naturally occurring
chromosomal DNA from a sample of human cells, and then
cleaving these long chromosomal DNA strands into shorter
47 See infra notes 78-85 and accompanying text.
48 See Structural Biochemistry/DNA Amplification Technique: Polymerase
Chain Reaction (PCR), WIKIBOOKS, http://en.wikibooks.org/wiki/StructuralBio
chemistry/DNA AmplificationTechnique:PolymeraseChainReaction (PCR)
(last visited Mar. 31, 2014).
N.C. J.L. & TECH.
fragments. 49 These fragments of naturally occurring DNA are then
inserted into DNA vectors capable of replication in a host cell. 0
The vectors containing the genomic DNA fragments are
subsequently introduced into cells, typically bacterial or yeast,
which can be grown in culture."1 Significantly, these genetically
modified cells are not naturally occurring, and like the genetically
modified cells at issue in Diamond v. Chakrabarty,5 2 they are not
products of nature. As these synthetic cells divide and replicate in
culture, the genetically modified recombinant vectors also
replicate, which results in amplification of the genomic DNA
sequence residing in the vector.53 Because the recombinant cell is
clearly "made by man" and not a product of nature under
Chakrabarty, copies of genomic DNA produced by replication of
the vectors are also not products of nature, but rather synthetic
molecules.
The resulting collection of recombinant cells, which comprises
cells containing vectors that harbor synthetic copies of genomic
DNA, is referred to as a "genomic DNA library."5 4 The cells
comprising the library contain DNA that retains the primary
sequence of genomic DNA, but the DNA molecules themselves
did not originate in the human chromosome, but instead were
synthesized as copies outside the body. Single cells can be isolated
from this mixture, and used to create a culture of cells which all
comprise the same fragment of genomic DNA. To isolate a gene
of interest, a biologist screens the library to identify and isolate a
pure cell culture that comprises a DNA fragment that includes that
gene. 5 6
49 See generally JOHN J. SAMBROOK ET AL., MOLECULAR CLONING: A




52 447 U.S. 303 (1980).
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Once the DNA sequence of a gene has been determined, there
is generally little reason to go back and repeat this process, because
the sequence information of the DNA can be used to synthesize
further copies by more convenient means. For example, as
described in a brief the author submitted in the first iteration of this
case, conventional BRCA genetic testing involves using techniques
such as PCR to amplify DNA molecules representing fragments of
a patient's full-length BRCA gene. 57 Furthermore, once the
sequence of a gene has been determined, the technology is
available to easily synthesize a DNA molecule corresponding in
sequence to the full-length gene."
To give a specific example, the Myriad patents describing the
initial "isolation" of the BRCA genes makes clear that what was
isolated was actually synthetic DNA having the same sequence of
nucleotides as native DNA, not native-origin genomic DNA. U.S.
Patent Number 5,747,282 ("the '282 patent"), for example,
describes how the inventors "isolated" the BRCAl gene from
synthetic, cloned DNA. 59 The '282 patent does not describe
isolating DNA by extracting it directly from native human
chromosome and to do so would make little sense, because that is
simply not how DNA was, or is, isolated. It is true that the process
of initially isolating the BRCA genes began with the extraction of
native chromosomal DNA from human cells, and cleavage of that
native DNA into fragments. But these are merely intermediate
steps in the preparation of the synthetic genomic DNA library and
it is this synthetic library from which the genes were actually
isolated.
5 See Brief for Christopher M. Holman & Robert Cook-Deegan as Amici
Curiae Supporting Neither Party at *16, Ass'n for Molecular Biology v. Myriad
Genetics, Inc., 133 S. Ct. 2107 (2013) (No. 2010-1406), 2010 WL 4853323; see
also Robert Cook-Deegan et al., supra note 20, at S16.
5 Home-Gene Design and Synthesis & Bioengineering-DNA 2.0, DNA
TWOPOINTO, INC., http://www.dna20.com (last visited Mar. 31, 2014).
59 U.S. Patent No. 5,747,282 col. 7, 1. 52 - col. 8, 1. 5 (filed June 7, 1995)
(describing how the inventors "isolated" the BRCA1 gene from cloned DNA
residing in yeast artificial chromosomes ("YACs"), bacterial artificial
chromosomes ("BACs"), P1 and cosmid clones (i.e., genomic DNA libraries),
and explaining that P1 clones were "isolated" using PCR primers).
N.C. J.L. & TECH.
If Myriad's holding is limited to DNA that has literally been
isolated from a natural source, thereby effectively maintaining the
status quo with respect to synthetic copies of genomic DNA, i.e.,
they are patent eligible, Myriad should have little if any impact on
genetic testing or biotechnology in general. 6 0 And although the
Supreme Court does not directly address this critical question,
there is reason to believe that this is the proper interpretation of the
decision. While neither the Supreme Court nor the Federal Circuit
explicitly defined the term "isolate," the district court defined
isolated DNA as "a segment of DNA nucleotides existing separate
from other cellular components normally associated with native
DNA, including proteins and other DNA sequences comprising the
remainder of the genome, and includes both DNA originating from
a cell as well as DNA synthesized through chemical or
heterologous biological means." 61 The district court's construction
of the term was dictated largely by language in Myriad's patent
specification that expressly defined "isolated DNA" as a DNA
molecule "'which is substantially separated from other cellular
components which naturally accompany a native human sequence
[such as] human genome sequences and proteins' and 'includes
recombinant or cloned DNA isolates and chemically synthesized
analogs or analogs biologically synthesized by heterologous
systems.' "62 The most plausible interpretation of these definitions
would seem to encompass naturally occurring DNA that originated
60 This is not the interpretation of recent PTO Guidance cited above, but as
stated, the courts will have the final word in interpreting Myriad, not the PTO.
61 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 217 (S.D.N.Y. 2010) aff'd in part, rev'd in part, 653 F.3d 1329
(Fed. Cir. 2011) cert. granted, judgment vacated sub nom. Ass'n for Molecular
Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012) and opinion vacated,
appeal reinstated, 467 F. App'x 890 (Fed. Cir. 2012) and aff'd in part, rev'd in
part, 689 F.3d 1303 (Fed. Cir. 2012) aff'd in part, rev'd in part sub nom.
Myriad, 133 S. Ct. 2107 (2013) (emphasis added).
62 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 216-17 (S.D.N.Y. 2010) aff'd in part, rev'd in part, 653 F.3d
1329 (Fed. Cir. 2011) cert. granted, judgment vacated sub nom. Ass'n for
Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012) and
opinion vacated, appeal reinstated, 467 F. App'x 890 (Fed. Cir. 2012) and aff'd
in part, rev'd in part, 689 F.3d 1303 (Fed. Cir. 2012) aff'd in part, rev'd in part
sub nom. Myriad, 133 S. Ct. 2107 (2013) (citing patent).
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in the genome of a naturally occurring human cell, and which has
been "isolated" in the sense of "purified" from other components
of a cell.
Neither the Supreme Court nor the Federal Circuit directly
address this issue, and this author suspects that the judges and
Justices are not sufficiently familiar with molecular biology to
recognize the ambiguity, compounded by the manner in which the
issue was obfuscated by the parties and amici, as illustrated by the
U.S. government's characterization of isolated DNA. 63 But
statements made by the Federal Circuit and Supreme Court suggest
that in deciding on the patent eligibility of isolated genomic DNA
the judges were focusing on native-source genomic DNA, rather
than synthetic copies of genomic DNA. 64 Writing for the Federal
Circuit majority, Judge Lourie stated that the term "isolated DNA"
refers to two types of DNA: (1) DNA that "has been cleaved (i.e.,
had covalent bonds in its backbone chemically severed)" from a
"larger, natural DNA molecule;" and (2) DNA that has been
"synthesized to consist of just a fraction of a naturally occurring
DNA molecule." 65 Judge Moore's concurring opinion similarly
referred to "the chemical differences between [naturally occurring]
and isolated DNA (breaking the covalent bonds)." 6 6
Significantly, although the district court and Federal Circuit
interpretations of "isolated DNA" appear to encompass both
native-origin and synthetic genomic DNA, the Supreme Court
appears to be only ruling on the patent eligibility of native-origin
genomic DNA. The Supreme Court never addresses or
acknowledges the existence of synthetic genomic DNA, but rather
focuses on its conclusion that Myriad's claims "would, if valid,
give it the exclusive right to isolate an individual's BRCAl and
BRCA2 genes (or any strand of 15 or more nucleotides within the
genes) by breaking the covalent bonds that connect the DNA to the
63 Brief for the United States as Amicus Curiae Supporting Neither Party,
Myriad, 133 S. Ct. 2107 (2013) (No. 12-398), 2013 WL 390999.
64 See supra notes 60 and 62.
6' Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689
F.3d 1329, 1351 (Fed. Cir. 2012) cert. granted in part, 133 S. Ct. 694 (2012)
and aff'd in part, rev'd in part sub nom. Myriad, 133 S. Ct. 2107 (2013).
66 Myriad, 133 S. Ct. at 2115.
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rest of the individual's genome." 67 The Court defined the "act of
isolating DNA [as] separating a specific gene or sequence of
nucleotides from the rest of the chromosome." 68 Consistent with
the lower court decisions, the Supreme Court characterizes the
claimed isolated molecules as DNA molecules that have been
"isolated" from the human genome by "sever[ing] chemical bonds
and "separating that gene from its surrounding genetic materials." 69
Although Myriad explicitly holds that synthetic cDNA is patent
eligible,70 it is silent on the patent eligibility of synthetic DNA in
general; and particularly with respect to synthetic genomic DNA.
A patent claim that encompasses both patent eligible and patent
ineligible subject matter is invalid, so a determination of invalidity
naturally flows from the Court's determination that (1) the
invalidated claims encompass native genomic DNA and (2) that
native genomic DNA is patent ineligible. But this in no way
implies that all isolated DNA encompassed by the invalidated
claims is patent ineligible. For example, the Supreme Court
explicitly upheld the validity of Claim 2 of U.S. Patent Number
5,747,282, directed towards cDNA, and because Claim 2 is
dependent upon patent ineligible Claim 1, then Claim 1 by
definition must encompass patent eligible subject matter, e.g., the
cDNA of claim 2.71 Myriad does not explicitly address the question
of whether synthetic genomic DNA is patent eligible, but it
certainly appears to leave the door open.
In fact, Myriad suggests that synthetic genomic DNA, and
synthetic DNA in general, should by and large be treated as patent
eligible subject matter.72 The Court repeatedly emphasizes that the
patent eligible cDNA claims are limited to "synthetic DNA created
in the laboratory" rather than native DNA cleaved from a naturally
occurring molecule.7 3 Justice Scalia's concurrence also seems to
hinge upon his understanding that cDNA "is a synthetic
6 7 Id. at 2113.
6 81 Id. at 2114-15.
69 1d. at 2117-18.
70 Id. at 2119.
71 35 U.S.C. § 112(d) (2013).
72 See supra, notes 68-70.
73 Myriad, 133 S. Ct. at 2112.
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creation."74 The Court points out that one distinction between
cDNA and the genomic DNA is that while "the natural creation of
mRNA involves splicing that removes introns, the synthetic
[cDNA] created from mRNA also contains only the exon
sequences."7 5 Significantly, however, the mRNA molecules which
are the template for the production cDNA are naturally occurring
molecules in their own right, no less than genomic DNA, and the
introns are removed from mRNA by natural processes in the cell,
not in a synthetic laboratory process.7 6 The nucleotide sequence of
cDNA, in other words, is identical to its naturally occurring mRNA
cognate. 77 To better understand how fundamentally similar
synthetic cDNA and synthetic genomic DNA are, it is useful to
understand what cDNA is and how it is prepared.
As explained in an amicus brief filed with the Federal Circuit
filed on behalf of the author, the methodology for producing
cDNA is entirely analogous to the methodology for isolating
genomic DNA.78 As a first step, mRNA is extracted from human
cells.7 9 This collection of mRNA molecules will comprise many
different sequences, generally representing all of the proteins that
are being expressed by the cells. 80 The extracted mRNA is
analogous to the extracted genomic DNA described above. mRNA
is structurally very similar to DNA, and contains the sequence
information of the gene." However, mRNA is a single-stranded
molecule that cannot self-replicate like DNA and is less chemically
stable.82 To address these issues, scientists use the extracted mRNA
molecules as templates to synthesize double-stranded cDNA
molecules retaining the sequence information of mRNA, but which
are more stable and can serve as a template for their own
74 Id. at 2120.
75 Id. at 2112.
76 SAMBROOK ET AL., supra note 49, Ch. 8.
7 7 Myriad, 133 S. Ct. at 2112.
78 Brief of Amicus Curiae Law Professor Christopher M. Holman, supra note
45.
79 Myriad, 133 S. Ct. at 2112.
so Id.
81 See generally BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL
(Garland Science 4th ed. 2002).
82 See supra note 78.
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replication.83 These double-stranded cDNA molecules are inserted
into vectors which are then introduced into cells, resulting in a
cDNA library entirely analogous to a genomic DNA library as
described above.8 4 This library can be screened to isolate a cDNA
corresponding to a gene of interest, e.g., a cDNA encoding a
BRCA protein."
Significantly, the resulting isolated cDNA is entirely analogous
to the claimed isolated genomic DNA. In both cases the DNA did
not actually originate in the cell, but it retains the informational
content of a native polynucleotide sequence. Specifically, cDNA
retains the mRNA nucleotide sequence, while the isolated genomic
DNA retains the nucleotide sequence of genomic DNA.
In an amicus brief filed with the Federal Circuit, the United
States argued that cDNAs are synthetic molecules "engineered" by
scientists to exclude introns and other regulatory regions, but in
fact, a cDNA is nothing more than a rote copy of a naturally
occurring mRNA molecule. 86 The "engineer[ing]" to exclude
introns and other regulatory regions is accomplished entirely
within the cell, by natural processes, in the cellular production of
mRNA, without any human intervention.87
In her concurring opinion, Judge Moore stated that Claim 2 of
the '282 patent can be distinguished from Claim 1 in that it is
limited to a cDNA molecule (1) having "a completely different
nucleotide sequence than the RNA" upon which it is based, and (2)
because "DNA has a different chemical structure than RNA,
including a different base (T instead of U, respectively) and sugar
units (deoxyribose instead of ribose, respectively)." 88 The first
purported distinction is based on a fundamental misunderstanding
of the nature of cDNA, perhaps attributable to the inadequate claim
83 Id.
84 SAMBROOK ET AL., supra note 49, at Ch. 8.
85 Id.
86 Brief for the United States, supra note 63, at *15.
87 Suzanne Clancy, RNA Splicing: Introns, Exons and Spliceosome, SCITABLE
(2008), http://www.nature.com/scitable/topicpage/rna-splicing-introns-exons-and-
spliceosome-12375.
8 U.S. Patent and Trademark Office v. Myriad Genetics, Inc., 653 F.3d 1329,
1364 (2011).
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construction that occurred at the district court. Isolated cDNA is
generally a double-stranded molecule, a first strand that is
complementary to the RNA in which it is based, and a second
strand having the identical sequence. 89 The '282 patent clearly
states that SEQ ID NO: 1 is the coding sequence for the protein,
i.e., is the same sequence as the mRNA.90
Regarding Judge Moore's second contention, it is true that
mRNA bears small chemical differences relative to DNA, but these
changes are of the same order as the difference between
methylated genomic DNA and its isolated counterpart discussed
above. The difference between deoxyribose and ribose is a single
oxygen atom; the difference between T and U (thymine and uracil)
is a methyl group attached to the ring at the 5 position.91 This is
essentially the same structural modification that occurs in the
methylation of genomic DNA, i.e., methylation at the 5 position in
the cytosine ring. The structural differences between RNA and
DNA are functionally significant, as reflected in the increased
stability of cDNA relative to RNA, but methylation of native
genomic DNA also performs an important functional role in
mediating epigenetic regulation of gene expression.92
Significantly, synthetic copies of genomic DNA have distinct
functional and structural characteristics that distinguish the copies
from native genomic DNA molecules. It is important to understand
that the information content of genomic DNA extends beyond the
primary sequence of nucleotides, i.e., the order in which G, A, T,
and C appear. 93 There are other structural modifications of genomic
DNA, referred to as epigenetics, which play an important role in
regulating gene expression in the native chromosome. 94 For
89 Id. at 1339.
90 Id. at 1334.
91 Structural Biochemistry/Nucleic Acid/Nitrogenous Bases/Pyrimidines/Thymine,
WIKIBOOKS, http://en.wikibooks.org/wiki/StructuralBiochemistry/Nucleic Acid/
Nitrogenous Bases/Pyrimidines/Thymine (last updated Oct. 30, 2011). Thymine
is another name for 5-methyluracil. Id.
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example, one of the most common epigenetic modifications of
human genomic DNA is methylation, a structural modification of
certain cytosine bases that occurs at millions of locations
throughout the native human genome.95 The methylation pattern of
genomic DNA plays a critical role in regulating gene expression
that not only varies from individual to individual, but also varies
from cell to cell in an individual and changes over time.
Significantly, the methylation pattern of human genomic DNA is
lost when it is amplified in a host cell (e.g., a DNA library) or by
laboratory techniques such as PCR. 96 Thus, the methylation of
genomic DNA, along with other epigenetic modifications, is not
retained in the isolated DNA. 97 In short, synthetic isolated DNA
not only does not originate from a native source, it is structurally
different in a way that significantly affects function.
B. Full-Length Coding Sequences vs. DNA Fragments
Even if Myriad is interpreted in a manner that renders patent
ineligible synthetic copies of genomic DNA, the vast majority of
so-called "gene patents" do not include any isolated DNA claim
that would be infringed by conventional genetic testing methods. 98
This is because most isolated DNA claims appear to only cover
full-length coding sequences that encode a full-length protein. 99
Full-length coding sequences can be important in some
applications, particularly when the objective is the recombinant
production of the encoded protein.100 These full-length sequences
are used to make protein drugs, such as recombinant
erythropoietin, or to make recombinant proteins for drug discovery
research, which was the subject matter of one of the Myriad
method claims that was challenged by the plaintiffs but was not at
95 Yingying Zhang & Albert Jeltsch, The Application of Next Generation
Sequencing in DNA Methylation Analysis, 1 GENES 85, 86 (2010).
9 6 Id. at 87.
97 Id.
98 Christopher M. Holman, Will Gene Patents Derail the Next-Generation of
Genetic Technologies?: A Reassessment of the Evidence Suggests Not, 80
UMKC L. REv. 563, 585 (2012).
99 Id.
10 0 Id.
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issue before the Supreme Court.101 The use of these full-length
sequences in drug development and production likely explains why
the U.S. government argued for patent eligibility of cDNA, which
is typically the form of the DNA used for recombinant protein
production.102 Significantly, however, conventional BRCA mutation
testing as it is currently practiced, which involves the amplification
and sequencing of relatively short fragments of the full-length gene
sequence, would not infringe claims limited to the full-length gene
sequence.103
Although most of Myriad's isolated DNA claims are limited to
full-length coding sequences, Myriad also has a claim that recites
shorter DNA fragments of full-length genes. 104 For example, Claim
5 of the '282 patent recites any "isolated DNA having at least 15
nucleotides of the [full length BRCA-encoding DNA sequence]."o5
This claim, on its face, purports to provide much broader coverage
than the full-length claims, and arguably encompasses
conventional BRCA mutation testing that involves the
amplification and analysis of DNA fragments as used in diagnostic
testing. If the claim is interpreted this broadly, however, it would
raise significant validity issues other than patent eligibility,
particularly under Sections 102, 103, and 112 of the patent
statute. 106
For example, a recent study found that 80 percent of the cDNA
and mRNA sequences that were contributed to GenBank (and
hence presumably published) before the effective filing date of the
'282 patent contain at least one DNA fragment falling within the
scope of Claim 5, and thus would apparently be encompassed by
101 U.S. Patent No. 5,747,282 col. 153 (filed June 7, 1995).
102 See infra Part IV.
103 See Brief for Christopher M. Holman & Robert Cook-Deegan, supra note
57; Robert Cook-Deegan et al., Impact of Gene Patents and Licensing Practices
on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing
Breast and Ovarian Cancers with Colon Cancers, 12 GENETICS MED. S15
(2010).
104 Ass'n of Molecular Biology v. Myriad Genetics, Inc., 133 S. Ct. 2107,
2113 (2013).
105 Id.
106 Brief for Christopher M. Holman & Robert Cook-Deegan, supra note 57,
at *4.
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the claim. 107 Follow-up studies have shown many "hits" of 15-mer
sequences in GenBank sequences that had already been deposited
more than a year before patent application, thus implicating 35
U.S.C. § 102(b).10 Thus, it appears that either this claim (and by
inference other claims directed to fragments of BRCA genes) is
invalid because it is not novel, or courts would have to interpret the
claim in a narrower sense than suggested by a plain reading of the
claim's language. More generally, enablement and written
description are the doctrinal tools conventionally deployed to
challenge overly broad patent claims, not patent eligibility. 109
Given the substantial questions regarding whether a court
would find fragment claims, such as Claim 5, valid and infringed
by conventional genetic diagnostic testing practices, it seems
unlikely that Myriad has really had much impact. The primary
motivation for obtaining DNA claims of this sort is to provide
protection against unauthorized use of the gene in the production
of recombinant protein, not diagnostic testing for genetic variations
in humans.110 As a result, there has never been a case in which the
issue of whether a diagnostic testing product or service infringes a
claim directed towards isolated human DNA, and in the absence of
case law it is difficult to know how a court would rule if actually
presented with such an issue. Significantly, extensive research by
the author has revealed that the majority of human gene patents do
not include short DNA fragment claims of this type, but instead
107 Thomas B. Kepler, Colin Crossman & Robert Cook-Deegan, Metastasizing
Patent Claims on BRCA], 95 GENOMICS 312, 312 (2010) (assuming implicitly
that entry in GenBank results in publication).
108 Thomas B. Kepler, Notes on the Bioinformatics of Gene Patents, DUKE U.
LIBRS., available at http://dukespace.lib.duke.edu/dspace/handle/10161/7775.
109 Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1203 (Fed. Cir. 1991)
(invalidating overly broad gene patent claim invalidated for lack of enablement);
Regents of the Univ. of California v. Eli Lilly & Co., 119 F.3d 1559, 1562 (Fed.
Cir. 1997) (invalidating overly broad gene patent claim for lack of adequate
written description).
110 This is presumably the main reason these claims exist in the patents. At the
time of the invention, BRCA was seen not only as a target for genetic diagnostic
testing, but also as a target for drug discovery, which would involve using the
full-length gene to produce recombinant protein for use in processes such as
those described in Claim 20.
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only have claims directed towards much longer DNA sequences
that generally are not inherently produced in genetic testing."
IV. WHY THE DICHOTOMY BETWEEN
ISOLATED GENOMIC DNA AND cDNA?
Given the similarity of cDNA and synthetic genomic DNA, it
is difficult to make a case that the two sorts of molecules should be
treated differently for purposes of patent eligibility. Nonetheless,
the Federal Circuit's Judge Bryson made this distinction and it was
adopted as the heart of the Supreme Court's decision. 112 The
genesis of the disparate treatment appears to have originated, at
least in part, from the amicus brief filed by the U.S. government
when the Federal Circuit first heard Myriad. 113 Although the
government's attempt to distinguish the two categories of DNA
molecules based on their chemical structure is unconvincing,1 14 the
better explanation for the government's position is that it was
attempting to maintain patent incentives for drug discovery while
eliminating broad patents in the area of genetic diagnostic testing.
As mentioned previously, cDNA is widely used in drug discovery
and drug production, and one can suspect that the government used
a distinction between cDNA and genomic DNA as a proxy for a
distinction between drugs and diagnostic testing, and the Court
acquiesced in this policy determination.
In biotechnology, gene patents often serve a function
analogous to the role of drug patents in the traditional
pharmaceutical industry. For example, most instances of human
gene patent infringement litigation have involved an innovator
biotechnology company enforcing its patent against a direct
competitor in order to maintain market exclusivity for a biologic
" Christopher M. Holman, Will Gene Patents Derail the Next-Generation of
Genetic Technologies?, supra note 98, at 585.
112 Id. at 570.
113 Brief for the United States as Amicus Curiae, supra note 63, at *15.
114 Brief of Amicus Curiae Law Professor Christopher M. Holman, supra note
45.
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drug developed by the patent owner. " Consistent with this
finding, two authoritative reports from the Congressional Office of
Technology Assessment, and a 2009 report issued by the Federal
Trade Commission, all concluded that gene patents have provided
the "fuel" for the "R&D engine" bringing biologic drugs to
patients.1 16
One of the landmark products of biotechnology, for example, is
recombinant erythropoietin, a biologic drug first brought to the
market in the 19 80s by Amgen under the trade name Epogen. 117
Recombinant erythropoietin was the product of groundbreaking
research conducted by Amgen, and this research required a
substantial investment of capital.' However, erythropoietin is a
naturally occurring human protein that was isolated prior to
Amgen's work, and the patent claiming isolated erythropoietin
protein per se expired around the time Amgen entered the market
with its recombinant product. As a consequence, Amgen has relied
primarily on gene patent protection to protect its product. 119 For
example, when another biotechnology company attempted to bring
a competing erythropoietin product to market in the U.S., Amgen
successfully sued for infringement of its patent claiming the
erythropoietin gene. 12 0 It bears noting that Amgen's core patent
11' Christopher M. Holman, The Impact ofHuman Gene Patents on Innovation
and Access: A Survey ofHuman Gene Patent Litigation, 76 UMKC L. REv. 295,
355 (2007).
116 OFFICE OF TECH. ASSESSMENT, U.S. CONGRESS, COMMERCIAL
BIOTECHNOLOGY: AN INTERNATIONAL ANALYSIS, OTA-BA-218 (1984); OFFICE
OF TECH. ASSESSMENT, U.S. CONGRESS, BIOTECHNOLOGY IN A GLOBAL
ECONOMY, OTA-BA-494 (1991); FED. TRADE COMM., EMERGING HEALTHCARE
ISSUES: FOLLOW-ON BIOLOGIC DRUG COMPETITION (2009). Although the FTC
Report does not specifically identify "gene patents" as the primary "fuel," every
example cited in the report of a biologic innovator successfully asserting its
patent against a competitor involved a gene patent. FED. TRADE COMM.,
EMERGING HEALTHCARE ISSUES: FOLLOW-ON BIOLOGIC DRUG COMPETITION 37
(2009).
117 Amgen, Inc. v. Chugai Pharm. Co., 706 F. Supp. 94, 104 (D. Mass. 1989).
"1 Amgen, Inc. v. Chugai Pharm. Co., No. 87-2617-Y, 1989 WL 169006, at
*7-*18 (Fed. Cir. Dec. 11, 1989).
119 Id
120 Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1212-14 (Fed. Cir.
1991).
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claim directed toward the gene, which the Federal Circuit held
infringed and not invalid in Amgen v. Chugai,12 1 is almost identical
to some of the composition of matter claims invalidated in
Myriad.122
V. METHOD CLAIMS AND MOLECULAR DIAGNOSTIC TESTING
For reasons discussed earlier, Myriad appears unlikely to have
much impact on patents in the genetic diagnostic testing and
personalized medicine space, to a large extent because most claims
directed to isolated genomic DNA molecules are not likely to be
infringed by conventional genetic testing. 123 Significantly, the
publication of the human genome sequence around the turn of the
century appears to have rendered patent claims directed towards
isolated human DNA largely unavailable for the protection of
human diagnostic discoveries, regardless of the patent eligibility of
isolated DNA. 12 4 But there remains a critical need for investment in
the discovery and commercialization of medically significant
correlations between biomarkers and medically significant
indications.125 The availability of methods claims for diagnostics
will play a critical role in this regard-without it, incentives for
investment in molecular diagnostics and personalized medicine
could be severely impacted.
Prior to Mayo, the Federal Circuit appeared to have adopted a
position such that a method claim reciting nothing more than a step
of identifying a biomarker correlated with a clinically significant
phenotype is patent ineligible. 126 However, the inclusion of
121 Id. at 1203.
122 Compare Amgen's U.S. Patent No. 4,703,008 Claim 2 (filed Nov. 30,
1984) ("A purified and isolated DNA sequence consisting essentially of a DNA
sequence encoding human erythropoietin.") with Myriad's U.S. Patent No.
5,747,282 Claims 1 and 2 (filed June 7, 1995).
123 See supra Part III.
124 Amicus Curiae Supporting Respondent at *5, Mayo, 132 S. Ct. 1289
(2012) (No. 10-1150), 2011 WL 5373694.
125 Id. at *4; see PERSONALIZED MEDICINE COALITION, THE CASE FOR
PERSONALIZED MEDICINE (3d ed. 2011), available at http://www.ageofpersonali
zedmedicine.org/objects/pdfs/CaseforPM_3rd-edition.pdf.
126 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347 (Fed.
Cir. 2010) rev'd, Mayo, 132 S. Ct. 1289 (2012).
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physical, transformative steps such as amplifying and/or analyzing
DNA, or using detection of the biomarker as the basis for some
treatment such as the administration of a drug to a patient,
generally appeared to be sufficient to render the claim patent
eligible.127 This position was grounded in sound innovation policy,
and more particularly in recognition that the availability of
effective patent protection plays a critical role in incentivizing
investment in the development of new molecular diagnostics and
personalized medicine. The Bilski v. Kappos 128 machine-or-
transformation test played a critical role in the Federal Circuit's
distinction between patent eligible and patent ineligible method
claims directed towards a medically significant biomarker
correlation. 129 For example, the use of a machine to detect the
biomarker, as occurs when DNA is analyzed, would be sufficient
to render the claim patent eligible. Similarly, the transformative
laboratory steps involved in analyzing DNA could be enough, as
would be the transformative step of administering a drug to a
patient.
This approach can be seen in the Federal Circuit's initial
decisions in Myriad and Mayo. In particular, when the Federal
Circuit first heard Myriad it upheld the validity of the isolated
DNA claims but struck down as patent ineligible all of the
challenged diagnostic method claims. 130 The case was decided
shortly after the Supreme Court issued its decision in Bilski,131 and
the Federal Circuit noted that although Bilski had rejected the
"machine-or-transformation test as the exclusive test for
determining whether an invention is a patent-eligible process," the
Court had recognized that the test remains "a useful and important
clue." 132 The Federal Circuit then proceeded to declare all of
12 7 Id. at *25.
128 130 S. Ct. 3218 (2010).
129 Mayo, 628 F.3d at 1349; see infra Part V.
130 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 653
F.3d 1329, 1358 (Fed. Cir. 2011), cert. granted, judgment vacated sub nom.
Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1704 (2012)
and opinion vacated, appeal reinstated, 467 F. App'x 890 (Fed. Cir. 2012).
131 Id.
13 2 Id. at 1355.
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Myriad's diagnostic method claims patent ineligible for being
directed towards abstract mental processes, and for failure to
satisfy the machine-or-transformation test.133
In particular, the court found that all of Myriad's diagnostic
method claims were broadly directed towards "comparing" or
"analyzing" to gene sequences, which the Federal Circuit
characterized as an abstract mental process, without the inclusion
of steps adequately incorporating a transformation or machine. 13 4
The court pointed to claim 1 of the '001 patent, which recites "a
'method for screening a tumor sample' by 'comparing' a first
BRCAl sequence from a tumor sample and a second BRCAl
sequence from a non-tumor sample, wherein a difference in
sequence indicates an alteration in the tumor sample."135 Myriad
argued that the claims implicitly required transformative steps of
extracting DNA from a human sample and sequencing the BRCA
DNA molecule. The Federal Circuit, however, found that the
claims did not recite any such steps, and the mere comparison or
analysis of raw sequence information, in the absence of any
physically transformative step, was insufficient for patent
eligibility. 13 6 The Federal Circuit strongly implied that the method
claims would have been found patent eligible if they had explicitly
included physically transformative steps of DNA analysis and
processing.137
In contrast, when the Federal Circuit decided Mayo, post-
Bilski, it found the claims patent eligible based on the inclusion of
"administering" and "determining" steps, which the Federal Circuit
characterized as transformative. 138 The court acknowledged that
under Bilski the machine-or-transformation test is not always
dispositive, but as the Supreme Court acknowledged, it remains a
useful tool for analyzing patent eligibility, and it was the primary






138 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 1352
(Fed. Cir. 2010), rev'd sub nom. Mayo, 132 S. Ct. 1289 (2012).
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of the diagnostic method claims at issue in Mayo.139 The Federal
Circuit recognized that the claim included a mental step of
recognizing a correlation between metabolite level and optimal
drug dosage, and that a claim that simply recited the mental step
would be patent ineligible. 14 0 This would be similar to the method
claims found patent ineligible by the Federal Circuit in Myriad.
The Federal Circuit went on to hold that the inclusion of a mental
step in a process does not render it patent ineligible, and that a
claim can be rendered patent eligible by the inclusion of a
transformative step-in this case, the "administering" and
"determining" steps recited in the claims were sufficiently
transformative to achieve this result. 14 1
With regard to claims including a step of administering drug to
a patient, the Federal Circuit held that "when administering a drug
... the human body necessarily undergoes a transformation ... In
fact, the transformation that occurs, viz., the effect on the body
after metabolizing the artificially administered drugs, is the entire
purpose of administering these drugs." 142 The court held that a
recited step of determining the level of drug metabolite in a patient
necessarily involves a transformation, and that the inclusion of a
determining step, thus, was independently sufficient to render the
patent claims patent eligible. 14 3 The court observed that:
[D]etermining the levels of [drug metabolite] in a subject necessarily
involves a transformation. Some form of manipulation, such as the high
pressure liquid chromatography method specified in several of the
asserted dependent claims or some other modification of the substances
to be measured, is necessary to extract the metabolites from a bodily
sample and determine their concentration. *
VI. MAYO AND MOLECULAR DIAGNOSTIC TESTING
Although the patent claims at issue in Mayo were not directed
toward genetic testing per se, they did recite methods of
139 Mayo, 628 F.3d at 1355.140 1d. at 1358.
141 Id. at 1355.
14 2 Id. at 1356.
143 Id. at 1357.
144 Id.
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non-genetic diagnostic testing as applied in the context of
personalized medicine. 145 As a general matter, however, three
aspects of Mayo in particular could severely limit the availability
of effective patent protection for innovations in genetic diagnostics
and personalized medicine. The first was the Court's
characterization of a correlation between the level of drug
metabolite in a patient's blood and the optimal drug dosage for that
patient as a "law of nature." 14 6 The second was its holding that in
order for a method claim based on the discovery of a law of nature
to be patent eligible it must incorporate an "inventive concept"
above and beyond the newly discovered law of nature. 147 Finally,
the third was the Court's holding that a method claim is patent
ineligible if it "preempts" a newly discovered law of nature. 148
It is important to bear in mind that the "metabolite" referred to
in Mayo is a non-naturally occurring molecule, essentially the
result of a synthetic drug being broken down by the body, and that
the Court in Mayo characterized the interaction of a non-naturally
occurring pharmaceutical compound with the human body as a law
of nature. 14 9 In taking this position, the Supreme Court is adopting
the finding of the Federal Circuit and district court. At the district
court level, the judge justified his conclusion that the correlation is
a natural phenomenon by noting that thiopurine drugs "are
converted naturally by enzymes within the patient's body to form
an agent that is therapeutically active, [and thus] the correlation
results from a natural body process." 150 In essence, the court
concluded that the mere involvement of a natural process in the
interaction between a man-made drug and the human body renders
the interaction a "natural phenomenon.""1
145 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 132 S. Ct. 1289,
1294 (2012).
14 6 Id. at 1296.
14 71Id. at 1294.
14 81Id. at 1296.
14 9 Id. at 1294.
150 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 2008 WL 878910 at
*6 (S.D. Cal. Mar. 28, 2008).
151 Id.
N.C. J.L. & TECH.
In an amicus brief filed with the Federal Circuit this author
argued that the district court's expansive definition of "natural
phenomena" seemed clearly incorrect, given that virtually every
patented invention is based on some discovery involving the
interaction of human ingenuity with the natural environment and
natural processes.152 The amicus brief pointed out that an airplane,
for example, interacts with the air in a particular manner that
results in flight.153 The air and its properties are natural phenomena,
but surely, that does not render the interaction of an airplane with
the air a natural phenomenon. 154 More to the point, what biological
or pharmaceutical invention is not based on an interaction with
natural biological processes? In particular, drugs operate by means
of chemical interactions with naturally occurring proteins and other
biomolecules in the body according to the fundamentals laws of
chemistry and biology. Unfortunately, neither the Federal Circuit
nor the Supreme Court adopted this view, and in characterizing the
interaction of a non-naturally occurring chemical compound with
the human body as a law of nature, the Supreme Court appears to
imply that the vast majority of personalized medicine inventions
are based on the discovery of a patent ineligible law of nature.
The Mayo Court's holding that a patent eligible method must
incorporate an "inventive concept" above and beyond the newly
discovered law of nature traces its origins back at least as far as the
Court's 1978 decision in Parker v. Flook,55 but Mayo's characterization
of the "inventive concept" test could be particularly problematic
for diagnostic inventions. This is because in applying the
"inventive concept" standard, the Mayo Court held that the
inclusion of method steps consisting of nothing more than "well
understood, routine, conventional activity already engaged in by
152 Brief for Interested Patent Law Professors as Amicus Curiae in Support of
Neither Party, Prometheus Labs. v. Mayo Collaborative Servs. (doing business
as Mayo Medical Laboratories) & Mayo Clinic Rochester, 628 F.3d 1347 (2010)
(No. 2008-1403), 2009 WL 462602.
153 Id. at *12.154 Id.
155 437 U.S. 584, 594 (1978) ("[T]he discovery of such a phenomenon cannot
support a patent unless there is some other inventive concept in its
application.").
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the scientific community[,]" which "when viewed as a whole, add
nothing significant beyond the sum of their parts taken separately,"
is insufficient to render a claimed method patent eligible. 15 6
The Supreme Court rejected the Federal Circuit's conclusion in
the decision below that the "administering" step was sufficiently
transformative to render the claims patent eligible. 157 To the
contrary, the Court characterized the "administering" step as
"simply refer[ring] to the relevant audience, namely doctors who
treat patients with certain diseases with thiopurine drugs. That
audience is a pre-existing audience; doctors used thiopurine drugs
to treat patients suffering from autoimmune disorders long before
anyone asserted these claims.""' The Court went on to explain
that, in "any event, 'the prohibition against patenting abstract ideas
cannot be circumvented by attempting to limit the use of the
formula to a particular technological environment.' "159
The Court also rejected the Federal Circuit's conclusion that
the "determining" step conferred patent eligibility on Prometheus'
claims. In the Court's view, the "determining" step simply "tells
the doctor to determine the level of the relevant metabolites in the
blood, through whatever process the doctor or the laboratory
wishes to use." 160 The Court found that methods for determining
levels of the metabolite in a subject's body were "well known in
the art" and routinely used by scientists, based upon statements
appearing in the patents. 16 1 The Court cited Flook and Bilski for the
proposition that "purely 'conventional or obvious' '[pre]-solution
activity' is normally not sufficient to transform an unpatentable
law of nature into a patent eligible application of such a law."162
Turning to the prohibition against preemption of fundamental
principles, the Court pointed to earlier precedent, such as
156 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 132 S. Ct. 1289,
1298 (2012).
157 Id. at 1303.
15 1Id. at 1297.
159 Id. (citing Diamond v Diehr, 450 U.S. 175, 191 (1981)) (internal quotation
marks omitted).
1 60 Id.
161 Id. at 1297-98.
16 2Id. at 1298.
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Gottschalk v. Benson,163 which warns against "upholding patents
that claim processes that too broadly preempt[s] the use of a
natural law." 16 4 According to Mayo, the problem with an overly
broad claim is that it might "inhibit further [innovation] by
improperly tying up the future use of laws of nature." 165 The Court
acknowledged that the laws of nature at issue in the case "are
narrow laws that may have limited applications," but still found
that if the claims at issue were found patent eligible there was a
danger that the patents would "tie up their use [and] inhibit future
innovation premised upon them." 166 According to the Court,
Prometheus' claims:
[T]ell a treating doctor to measure metabolite levels and to consider the
resulting measurements in light of the statistical relationships they
describe. In doing so, they tie up the doctor's subsequent treatment
decision whether that treatment does, or does not, change in light of the
inference he has drawn using the correlations. And they threaten to
inhibit the development of more refined treatment recommendations
(like that embodied in Mayo's test), that combine Prometheus'
correlations with later discovered features of metabolites, human
physiology or individual patient characteristics. The "determining" step
too is set forth in highly general language covering all processes that
make use of the correlations after measuring metabolites, including
later discovered processes that measure metabolite levels in new
ways. 167
Fortunately, Mayo includes passages that offer some hope that
some diagnostic testing and personalized medicine method claims
might still be found patent eligible post-Mayo. In particular, the
Court did not overrule Diamond v. Diehr,168 an important 1981
decision finding a computer program patent eligible. 169 In the
minds of many, the inventions in Diehr and Flook are virtually
indistinguishable from the perspective of patent eligibility. In
seeking to reconcile them, the Mayo court suggested that the Diehr
163 409 U.S. 63 (1972).
164 Mayo, 132 S. Ct. 1289, 1294 (citing Gottschalk v. Benson, 409 U.S. 63
(1972)).
16 51 d. at 1301.
16 6 Id. at 1301-02.
16 7 Id. at 1302.
168 450 U.S. 175 (1981).
1 69 Id.
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claims were patent eligible because the Diehr majority never
suggested that all the steps, or at least the combination of steps
recited in the claims "were in context obvious, already in use, or
purely conventional." 17 0 Mayo concludes that "[t]hese other steps
apparently added to the formula something that in terms of patent
law's objectives had significance-they transformed the process
into an inventive application of the formula."171
The Court also made clear that it "need not, and [had] not, now
decide[d] whether were the steps at issue here less conventional,
these features of the claim would prove sufficient to invalidate
them."17 2 The Court took pains to emphasize that it did not intend
its decision to eliminate patent protection for new drugs or new
uses of existing drugs, opining that unlike patents on drugs, the
Prometheus claims "do not confine their reach to particular
applications."173 Thus, under Mayo it still seems possible that an
applicant for a diagnostic testing method claim could successfully
argue that, unlike the Prometheus claims, the applicant's claims
include steps that "in context" introduce something nonobvious or
unconventional into the claim, thereby adding something of
significance "in terms of patent law's objectives."1 7 4 The statement
favoring the patenting of drugs might be cited for the proposition
that a personalized medicine claim that is perhaps more inventive
and/or less preemptive than the Prometheus claims might still pass
muster post-Mayo.
The Federal Circuit's Chief Judge Rader appears to have
adopted a permissive interpretation of Mayo that would tend to
preserve the patent eligibility of many diagnostic tests and
personalized medicine inventions.175 In an opinion he authored in
CLS Bank Int'l. v. Alice Corp. Pty. Ltd.,17 6 Judge Rader explained
that the "inventive concept" language used in Mayo "should not be
170 Mayo, 132 S. Ct at 1299.
171 Id.
17 21 d. at 1302.
173 Id.
17 4 jd. at 1299.
175 See generally CLS Bank Int'l. v. Alice Corp. Pty. Ltd., 717 F.3d 1269
(Fed. Cir. 2013).
176 717 F.3d 1269 (Fed. Cir. 2013).
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read to conflate principles of patent eligibility with those of
validity, [n]or should it be read to instill an 'inventiveness' or
'ingenuity' component into the inquiry."177 Citing to Diehr, Judge
Rader argued that:
Because a new combination of old steps is patentable, as is a new
process using an old machine or composition, subject matter eligibility
must exist even if it was obvious to use the old steps with the new
machine or composition. Otherwise the eligibility analysis ignores the
text of sections 101 and 100(b), and reads Section 103 out of the Patent
Act. 178
According to Judge Rader, "[t]he Supreme Court's reference to
'inventiveness' in [Mayo] must be read as shorthand for its inquiry
into whether implementing the abstract idea in the context of the
claimed invention inherently requires the recited steps." 179
Chief Judge Rader also proffered a relatively narrow
interpretation of the preemption test articulated in Mayo. In his
view, "the question for patent eligibility is whether the claim
contains limitations that meaningfully tie that idea to a concrete
reality or actual application of that idea."18 0 He acknowledged that
"if a claim covers all practical applications of an abstract idea, it is
not meaningfully limited," but he went on to clarify that the
question is whether a "claim covers every practical application of
[a fundamental principle],""1 such that the claim would necessarily
be infringed by anyone wanting to use the principle. In a nod to
the Bilski machine-or-transformation test, he argued that "a claim
is meaningfully limited if it requires a particular machine
implementing a process or a particular transformation of matter."182
177 Id. at 1302. (Rader, C.J., concurring in part and dissenting in part).
17 81 d. at 1303.
179 Id.
0 Id. at 1299-1300.
Id. at 1300.
182Id. at 1301.
672 [VOL. 15: 639
JUNE 2014] Mayo, Mrj iad, and the Future of Innovation 673
VII. ARIOSA DIAGNOSTICS THREATENS INNOVATION IN
DIAGNOSTIC-BASED INVENTIONS
A recent decision from the Northern District of California,
Ariosa Diagnostics, Inc. v. Sequenom, Inc.,183 provides a sobering
example of an aggressive application of Mayo that, if adopted
broadly, could severely impact the availability of effective patent
protection for future innovations in molecular diagnostic testing
and personalized medicine. The patent at issue in Ariosa
Diagnostics, U.S. Patent Number 6,258,540 ("the '540 patent"), 18 4
was based on the discovery by researchers at Oxford University
that the blood of a pregnant woman contains substantial quantities
of cell-free fetal DNA ("cffDNA") and their recognition that
cffDNA could be used in pre-natal diagnostic testing of paternally-
inherited DNA for purposes such as sex determination, genotyping,
and detection of pre-eclampsia in the mother.' Oxford University
licensed the patent to Sequenom, Inc., a San Diego-based
genomics company. 186 Ariosa Diagnostics sued Sequenom in a
declaratory judgment action seeking a declaration that its
Harmony TM test, a non-invasive cffDNA-based prenatal test, does
not infringe the '540 patent. 187
On motion for summary judgment, the district court declared a
number of the claims in the Sequenom patent invalid for being
drawn to patent ineligible subject matter.' The court began its
analysis by assuming, per agreement of the parties, that "the
presence of cffDNA in maternal plasma or serum is a natural
phenomenon."1 89 It then proceeded to find the challenged method
183 2013 WL 5863022 (N.D. Cal. Oct. 30, 2013) [hereinafter Ariosa
Diagnostics].
184 The original assignee, Isis Innovation Limited, is the technology transfer
division for Oxford University. ISIS INNOVATION LTD., http://www.isis-
innovation. com/ (last visited Mar. 30, 2014).
"' Ariosa Diagnostics, 2013 WL 5863022, at *1.
186 Id.; see SEQUENOM, http://www.sequenom.com/ (last visited Mar. 30,
2014).
187 Ariosa Diagnostics, 2013 WL 5863022, at *1.
' Id. at *10.
189 Id. at *7.
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claims patent ineligible for failure to satisfy the "inventive
concept" and "preemption" standards articulated in Mayo. 190
In applying the "inventive concept" test, the court essentially
treated the natural phenomenon of cffDNA as part of the prior art,
holding that "use of a newly discovered natural phenomenon ...
will not render a claim patentable if the use of that natural
phenomenon ... is the only innovation contained in the patent." 19 1
The claims required steps of amplifying and detecting paternal
effDNA, but the court found that amplification and detection of
DNA are conventional techniques "previously engaged in by those
in the field," and thus not sufficiently inventive to render the
claims patent eligible. 192 The court concluded that use of a newly
discovered natural phenomenon will not render a claim patentable
if its use "is the only innovation contained in the patent." 19 3
Turning to the "preemption" test, the district court found the
claims patent ineligible based on the patent owner's failure to
present evidence of "commercially viable," non-infringing
methods of testing for paternal cffDNA. 194 The court was not
entirely clear as to when the commercially viable, non-infringing
alternatives needed to be available, but strongly implied that in
order to satisfy the patent eligibility doctrine, the patent owner was
required to establish that such methods "existed at the time of the
invention or at the time of issuance of the patent." 195 The
"commercially viable" standard applied by the court appears to be
substantially more stringent than the preemption test as envisioned
by judges on the Federal Circuit. For example, in CLS Bank v.
Alice, Chief Judge Rader emphasized that preemption only occurs
under circumstances such that "the claim covers every practical
application of [the fundamental principle] ."196 Sequenom apparently
presented evidence of practical non-infringing methods of testing
190 Id. at *7, *11.
191 Id. at *9.192 id. at *8.
193 Id. at *9.
19 4 Id. at *11.195 Id.
196 CLS Bank Int'l. v. Alice Corp. Pty. Ltd., 717 F.3d 1269, 1299-1302 (Fed.
Cir. 2013) (Rader, C.J., concurring in part and dissenting in part).
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for cffDNA, which would seem to satisfy Judge Rader's "practical
application" test, but the court disregarded them based on
Sequenom's failure to establish commercially viability. 197
The Sequenom patent is not entirely representative of the
majority of genetic diagnostic testing patents, it is not based on the
discovery of a correlation between a genetic variation (or
combination of genetic variations) and some clinically significant
phenotype. Still, Ariosa Diagnostic's interpretation of Mayo does
not bode well for a broad swath of diagnostic testing and
personalized medicine patents. The Federal Circuit's initial Myriad
decision invalidated method claims that broadly recited methods of
identifying variations in BRCA genes associated with a
predisposition to cancer.198 But Mayo was decided in sufficiently
vague terms that it seems possible that method claims explicitly
reciting physical steps of processing and analyzing the DNA
and/or applying the knowledge that variation exists (for example
by treating the patient) would remain patent eligible post-Mayo.
The Supreme Court itself suggested as much in Myriad, when it
noted with approval an assertion by the Federal Circuit's Judge
Bryson that "many of [Myriad's unchallenged patent] claims" are
patent eligible. 199 In particular, Judge Bryson explicitly pointed to
Claim 21 of U.S. Patent Number 5,753,441 as an example of a
patent eligible claim.2 00 Claims 20 and 21 recite:
A method for detecting a germline alteration in a BRCA1 gene, said
alteration selected from the group consisting of the alterations set forth
in Tables 11 and 12 which comprises analyzing a sequence of the
BRCA1 gene or BRCA1 RNA from a human sample or analyzing the
sequence of BRCA1 CDNA made from mRNA from said sample[,] ...
wherein a germline alteration is detected by hybridizing a BRCA1 gene
probe which specifically hybridizes to an allele of one of said
alterations to RNA isolated from said human sample and detecting the
197 See Ariosa Diagnostics, 2013 WL 5863022, at *11.
198 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 653
F.3d 1329, 1355-56 (Fed. Cir. 2011).
199 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107,
2120 (2013).
200 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689
F.3d 1303, 1349 (Fed. Cir. 2012) (Bryson, J., concurring in part and dissenting
in part).
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presence of a hybridization product, wherein the presence of said
product indicates the presence of said allele in the sample.201
The only additional element incorporated into the method of
Claim 21 beyond identification of a germline alteration
(presumably a law of nature under Mayo) is detection by means of
a hybridization probe, which has long been a conventional method
for analyzing DNA. 2 02 It would seem to be no more of an inventive
concept than the hybridization and detection recited in the
Sequenom claims. In fact, Sequenom argued that some of its
claims must be valid if Judge Bryson is correct with respect to the
patent eligibility of Claim 21, but the district court judge rejected
this argument in a footnote, noting that, in Myriad, Justice Thomas
did not specifically identify Claim 21 as one of the claims with
regard to which he agreed with Judge Bryson's opinion of
validity.203
With respect to the issue of preemption, Ariosa Diagnostics'
"commercially viable" standard could also prove problematic,
because a patent that fails to encompass a commercially viable
means for detecting the genetic variation might very well be of
limited value in blocking market entry by competitors. The court's
application of the preemption test essentially turns the logic of
Mayo on its head. While Mayo emphasized that the policy behind
the preemption test is to prevent an inventor from "improperly
tying up the future use of laws of nature," 204 the Ariosa court has
essentially held that an inventor is not even allowed to tie up
currently available and "commercially viable" applications of a
law of nature, even if the claim allows for the development of
noninfringing future uses. 205
One particularly troubling aspect of Ariosa Diagnostics is the
way that the court used statements by Sequenom management as
evidence of preemption. Apparently company management had
201 U.S. Patent No. 5,753,441 col.157 (filed May 19, 1998).
202 See generally SAMBROOK ET AL., supra note 49 (providing comprehensive
protocols and techniques for laboratories working with DNA).
203 Ariosa Diagnostics, 2013 WL 5863022, at *10, n.8.
204 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 132 S. Ct. 1289,
1301 (2012).
205 See Ariosa Diagnostics, 2013 WL 5863022.
676 [VOL. 15: 639
JUNE 2014] Mayo, Mrj iad, and the Future of Innovation 677
made statements outside the context of the litigation touting the
breadth of its claims, and the court used these as evidence of
preemption.2 06 Sequenom presumably made substantial investments
in licensing the patent from Oxford and commercializing the
technology, and perhaps this would not have occurred if the
company did not believe it had reasonably broad coverage. In the
same vein, perhaps investors would not have invested in the
company in the first place if they had realized they would not be
able to preclude other companies from easily tapping into the
market.
Ariosa Diagnostics also appears to pose substantial
impediments to the patenting of innovations in personalized
medicine, an increasingly promising application of diagnostic
testing.2 07 A typical personalized medicine invention is based on
the discovery of some genetic variation that is predictive of
optimal medical treatment, oftentimes in terms of the best drug for
a particular patient, or the optimized dosage for that patient.2 08 But
the Mayo Court's interpretation of law of nature suggests that
personalized medicine discoveries will be characterized as patent
ineligible natural phenomena. Because the techniques used to
apply such a discovery in the form of personalized medicine are
typically conventional, a court applying the Ariosa Diagnostics
standard for analyzing "inventive concept" would likely find the
typical personal medicine claim invalid for lack of patent
ineligibility.
VIII. CONCLUSION
Although many view Myriad as a case with important
implications for genetic diagnostic testing, it seems more likely
that Mayo will prove to be the more significant decision in this
regard. Ariosa Diagnostics provides an example of a stringent
application of Mayo that, if affirmed by the Federal Circuit and
206 Id at *11.
207See PERSONALIZED MEDICINE COALITION, THE CASE FOR PERSONALIZED
MEDICINE (3d ed. 2011), available at http://www.ageofpersonalizedmedicine.
org/objects/pdfs/CaseforPM_3rd edition.pdf.
208 Id.
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broadly adopted, could substantially impact the availability of
effective patent protection for molecular diagnostics and
personalized medicine. This, in turn, could adversely affect
investment in innovation in this critical aspect of healthcare. Mayo
is amenable to a much more restrained interpretation that would
largely preserve patentability for truly innovative diagnostic-based
inventions, and one hopes that if the Federal Circuit has an
opportunity to review Ariosa Diagnostics, it will reverse the
decision and recalibrate the standard for patent eligibility in this
important area of technology.

